Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aviscumine - MELEMA Pharma

Next Previous
X
Search
Drug Profile

Aviscumine - MELEMA Pharma

Alternative Names: BA503; CY-503; ME-503; Mistletoe lectin recombinant; Recombinant mistletoe lectin; Recombinant viscumin; Recombinant viscumine; rViscumin; Viscum ribosome inactivating protein

Latest Information Update: 05 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator VISCUM AG
  • Developer MELEMA Pharma GmbH; University of Texas M. D. Anderson Cancer Center; University of Tubingen
  • Class Antineoplastics; Biological toxins; Lectins; Plant proteins
  • Mechanism of Action 28S ribosomal RNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Colorectal cancer; Malignant melanoma; Solid tumours
  • Phase I/II Bladder cancer; Malignant pleural effusion
  • Preclinical Cancer; Glioblastoma; Liver cancer; Lung cancer; Sarcoma

Most Recent Events

  • 05 Jan 2022 Phase-I/II clinical trials in Bladder cancer in Germany (Topical) as of January 2022 (MELEMA Pharma pipeline; January 2022)
  • 05 Jan 2022 Phase-I/II clinical trials in Malignant pleural effusion in Germany (SC) as of January 2022 (MELEMA Pharma pipeline; January 2022)
  • 05 Jan 2022 Phase-II clinical trials in Solid tumours (Second-line therapy or greater) in Germany (SC) as of January 2022 (MELEMA Pharma pipeline; January 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top